Circulating microRNA expression profile: a novel potential predictor for chronic nervous lesions

Xu, Yongming; Zhang, Xin; Pu, Shaofeng; Wu, Junzhen; Lv, Yingying; Du, Dongping

doi:10.1093/abbs/gmu090

Cited by 25 publications

(24 citation statements)

References 52 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Serum miR-221 was decreased and moderate negatively correlated with plasma hs-CRP in acute ischemic stroke patients 17 ; miR-221 in the serum of rats after spinal nerve ligation surgery was decreased. 18 Thus, our findings further supported that serum miR-221 may be a potential predictor for disease. In addition, serum miR-221 was positive correlated with UPDRS-III and UPDRS-V scores, although miR-221 was downregulated in serum of most PD patients.…”

Section: Discussionsupporting

confidence: 76%

“…In addition, upregulated miR‐195 and downregulated miR‐185, miR‐15b, miR‐221, and miR‐181a can precisely distinguish PD patients from health individuals and may be used as a potential serum‐based biomarker for the diagnosis of PD . Serum miR‐221 was decreased and moderate negatively correlated with plasma hs‐CRP in acute ischemic stroke patients; miR‐221 in the serum of rats after spinal nerve ligation surgery was decreased . Thus, our findings further supported that serum miR‐221 may be a potential predictor for disease.…”

Section: Discussionsupporting

confidence: 76%

See 1 more Smart Citation

Serum miR‐221 serves as a biomarker for Parkinson's disease

Wang

et al. 2016

Cell Biochemistry & Function

View full text Add to dashboard Cite

Parkinson's disease (PD) is the common age-related neurodegenerative disorder. Sensitive, noninvasive biomarkers that facilitate PD diagnosis and stage assignment are currently unavailable. This study aims to investigate the potential of 16 previous reported PD-associated miRNAs as novel biomarkers for PD. The expression of 16 serum miRNAs was measured by quantitative reverse transcriptase polymerase chain reaction in 138 PD patients and 112 control populations. Analyses were undertaken to assess the specificity and sensitivity of miRNAs to predict PD. In addition, the relationship between deregulated miRNAs and Part III of the United Parkinson's Disease Rating Scale (UPDRS-III) and Part V of the UPDRS (UPDRS-V; the modified Hoehn and Yahr staging of PD) in PD patients was also assessed. It was found that the serums miR-29c, miR-146a, miR-214, and miR-221 were significantly decreased in PD patients compared with healthy control populations. In addition, serum miR-221 was positively correlated with UPDRS-III (r = .4702) and UPDRS-V (r = .4788) score in PD patients. Furthermore, the receiver operating characteristic result of serum miR-221 for prediction of PD was 0.787. Our preliminary findings indicate that downregulated serum miR-221 might be a potential biomarker for PD evaluation.

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Discussionsupporting

confidence: 76%

Serum miR‐221 serves as a biomarker for Parkinson's disease

Wang

et al. 2016

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…MiR-133b has been regarded as an important predictor to diagnose and characterize several diseases [17-19]. Recently, a study utilizing bioinformatics data indicated that six circulating miRs, including miR-133b, were most predictive of allergic status, and miR-133b showed decreased plasma level in AR patients [19].…”

Section: Discussionmentioning

confidence: 99%

“…Specifically, accumulating evidences suggest that miR-133b may be a novel potential predictor for inflammation. A previous study indicated that the changes of miR-133b expression might involve in the regulation of neuropathic pain, which were correlated with the expression of inflammatory cytokines [17]. Downregulation of miR-133b could be observed in the muscle of patients with inflammatory myopathy [18].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-133b Ameliorates Allergic Inflammation and Symptom in Murine Model of Allergic Rhinitis by Targeting Nlrp3

Xiao¹,

Jiang²,

Hu³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: Emerging evidences indicate that post-transcriptional regulation by microRNAs is critical in allergic rhinitis (AR) pathogenesis. MircroRNA-133b (miR-133b) was recently suggested as a potential predictor of AR. However, the in vivo effect of miR-133b on AR is unclear. Methods: AR model was established in BALB/c mice by intraperitoneal sensitization and intranasal challenge with ovalbumin (OVA). MiR-133b agomir was then intranasally administrated to mice after OVA challenge for another 7 days. The symptom of nasal rubbing and sneezing were recorded after the last OVA challenge. Nasal mucosa tissues and serum were collected. MiR-133b expression, serum OVA-specific immunoglobulin E (IgE) concentration, proinflammatory cytokines (TNF-α, IL-4, IL-5, IL-10 and IFN-γ) levels, and Nlrp3 inflammasome activation were measured by RT-PCR, ELISA, western blotting or immunohistochemistry, respectively. Histopathologic changes were evaluated using hematoxylin and eosin and Sirius red staining. The luciferase activity and protein expression of Nlrp3 were also determined. Results: MiR-133b expression was significantly decreased in nasal mucosa of AR mice, which was restored by nasal administration with miR-133b agomir. Upregulation of miR-133b markedly reduced the concentration of OVA-specific IgE, the frequencies of nasal rubbing and sneezing, and the levels of cytokines (TNF-α, IL-4, IL-5 and IFN-γ). Levels of IL-4, IL-5, IL-10 and IFN-γ produced by cervical lymph node cells were significantly lowered in miR-133b agomir-treated mice. Moreover, miR-133b also appeared to strongly attenuate pathological alterations and eosinophils and mast cells infiltration in nasal mucosa. Notably, we demonstrated for the first time that miR-133b negatively regulated Nlrp3 expression through binding with the 3’ untranslated region of Nlrp3. Consequently, infection of miR-133b in nasal mucosa remarkably suppressed the Nlrp3 inflammasome activation, as evidenced by reduced Nlrp3, Caspase-1, ASC, IL-18 and IL-1 expressions. Conclusion: MiR-133b alleviates allergic symptom in AR mice by inhibition of Nlrp3 inflammasome-meditated inflammation. These findings provide us an insight into the potential role of miR-133b in relation to AR treatment.

show abstract

“…IL-1β, a proinflammatory cytokine, is elevated in patients with neuropathic pain (105). IL-6 is upregulated in human and rat neuropathic nerves (105, 107), and in CSF of human CPRS (106) (complex regional pain syndrome) as well as in serum of nerve-injured rats (108);, gene knockout of IL-6 attenuates allodynia in the SNL mouse model (109). Monocyte chemoattractant protein-1 (MCP-1), a biomarker for human CRPS, is also upregulated in rats (108, 110).…”

Section: Human Chronic Pain and Dynorphinmentioning

confidence: 99%

The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective

Podvin

Yaksh²,

Hook

2016

Annu. Rev. Pharmacol. Toxicol.

View full text Add to dashboard Cite

Notable findings point to the significance of the dynorphin peptide neurotransmitter in chronic pain. Spinal dynorphin neuropeptide levels are elevated during development of chronic pain. Importantly, knockout of the dynorphin gene prevents development of chronic pain in mice, but acute nociception is unaffected. Intrathecal (IT) administration of opioid and non-opioid dynorphin peptides initiate allodynia through a non-opioid receptor mechanism; furthermore, anti-dynorphin antibodies administered by the IT route attenuate chronic pain. Thus, this review presents the compelling evidence in the field supporting the role of dynorphin in facilitating the development of a persistent pain state. These observations raise the question of the control mechanisms responsible for the upregulation of spinal dynorphin leading to chronic pain development. Also, spinal dynorphin regulation of downstream signaling molecules may be implicated in hyperpathic states. Therapeutic strategies to reduce spinal dynorphin may provide a non-addictive approach to improve the devastating condition of chronic pain that occurs in numerous human diseases.

show abstract

Circulating microRNA expression profile: a novel potential predictor for chronic nervous lesions

Cited by 25 publications

References 52 publications

Serum miR‐221 serves as a biomarker for Parkinson's disease

Serum miR‐221 serves as a biomarker for Parkinson's disease

MicroRNA-133b Ameliorates Allergic Inflammation and Symptom in Murine Model of Allergic Rhinitis by Targeting Nlrp3

The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective

Contact Info

Product

Resources

About